精品文档---下载后可任意编辑XRCC1、ERCC5 基因多态性与晚期 NSCLC 患者化疗疗效的相关性讨论的开题报告摘要：晚期非小细胞肺癌（NSCLC）患者的化疗疗效受到多种因素的影响，其中基因多态性是一个重要的因素。XRCC1 和 ERCC5 是与 DNA 修复相关的基因，其多态性在 NSCLC 患者中较为常见。本讨论旨在探讨XRCC1 和 ERCC5 基因多态性与晚期 NSCLC 患者化疗疗效的相关性。本讨论将纳入 100 例晚期 NSCLC 患者，进行 DNA 检测分析XRCC1 Arg194Trp 和 ERCC5 Asp1104His 的基因多态性分布情况，并根据患者化疗后 3 个月的疗效评估结果，将患者分为有效组和无效组。采纳统计学方法分析 XRCC1 和 ERCC5 基因多态性与化疗疗效之间的关系。估计讨论结果将有助于探讨 XRCC1 和 ERCC5 基因多态性对晚期NSCLC 患者化疗疗效的影响，为临床化疗方案的制定提供参考。关键词：XRCC1、ERCC5、基因多态性、非小细胞肺癌、化疗疗效Abstract：Chemotherapy efficacy in advanced non-small cell lung cancer (NSCLC) patients is influenced by multiple factors, among which genetic polymorphisms are important factors. XRCC1 and ERCC5 are genes related to DNA repair, and their polymorphisms are common in NSCLC patients. This study aims to explore the correlation between XRCC1 and ERCC5 gene polymorphisms and chemotherapy efficacy in advanced NSCLC patients.This study will include 100 cases of advanced NSCLC patients. DNA testing will be conducted to analyze the distribution of XRCC1 Arg194Trp and ERCC5 Asp1104His gene polymorphisms. Based on the 3-month efficacy evaluation results of chemotherapy, patients will be divided into effective and ineffective groups. Statistical methods will be used to analyze the relationship between XRCC1 and ERCC5 gene polymorphisms and chemotherapy efficacy.The expected research results will help to explore the influence of XRCC1 and ERCC5 gene polymorphisms on chemotherapy efficacy in advanced NSCLC patients, and 精品文档---下载后可任意编辑provide references for the formulation of clinical chemotherapy regimens.Keywords: XRCC1, ERCC5, gene polymorphism, non-small cell lung cancer, chemotherapy efficacy
